Physician profile
Charles E Manner
NPI 1760443782
$13,100.11
in general payments reported to CMS, 2019-2025
70 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,305 · 2020: $1,545 · 2021: $3,441 · 2022: $4,386 · 2023: $253 · 2024: $68.87 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $423.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,139.26 | 2019-2022 | |
| Janssen Biotech, INC. | $932.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $737.92 | 2019-2022 | |
| Amgen INC. | $718.36 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $708.60 | 2019-2022 | |
| Celgene Corporation | $665.11 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $626.43 | 2019-2023 | Opdivo |
| Genzyme Corporation | $582.86 | 2019-2022 | |
| Pfizer INC. | $512.72 | 2019-2022 | |
| Glaxosmithkline, LLC. | $509.33 | 2020-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $388.12 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $363.69 | 2019-2022 | |
| Eisai INC. | $338.13 | 2019-2022 | |
| Beigene USA, INC. | $307.02 | 2020-2024 | Brukinsa |
| Seagen INC. | $275.51 | 2019-2022 |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Manner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.